In this editorial the author examines the initiatives taken by Drugs for Neglected Diseases (DNDi) and Medicines Patent Pool (MPP) organizations to improve access to pan-genotypic hepatitis C treatment.
Browsing: Viral > Hepatitis
The most common cause of hepatitis is viruses, which can be spread sexually, through contaminated food, water, or through infected blood
0 DNDi, MPP speed up in hepatitis C pan-genotypic treatment access
0 Pharmacogenetics of ribavirin-induced anemia in HCV patients
In this review the authors look into the potential use of pharmacogenomics in predisposing ribavirin-treated hepatitis C patients to anemia.